Re: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

被引：0
|
作者：
Chang, Sam S.
机构：
来源：
JOURNAL OF UROLOGY | 2021年 / 206卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1518 / 1519
页数：2
相关论文
共 50 条
  • [1] Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
    Motzer, Robert
    Alekseev, Boris
    Rha, Sun-Young
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Gruenwald, Viktor
    Hutson, Thomas E.
    Kopyltsov, Evgeny
    Mendez-Vidal, Maria J.
    Kozlov, Vadim
    Alyasova, Anna
    Hong, Sung-Hoo
    Kapoor, Anil
    Alonso Gordoa, Teresa
    Merchan, Jaime R.
    Winquist, Eric
    Maroto, Pablo
    Goh, Jeffrey C.
    Kim, Miso
    Gurney, Howard
    Patel, Vijay
    Peer, Avivit
    Procopio, Giuseppe
    Takagi, Toshio
    Melichar, Bohuslav
    Rolland, Frederic
    De Giorgi, Ugo
    Wong, Shirley
    Bedke, Jens
    Schmidinger, Manuela
    Dutcus, Corina E.
    Smith, Alan D.
    Dutta, Lea
    Mody, Kalgi
    Perini, Rodolfo F.
    Xing, Dongyuan
    Choueiri, Toni K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (14): : 1289 - 1300
  • [2] Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale
    Grunwald, Viktor
    Powles, Thomas
    Choueiri, Toni K.
    Hutson, Thomas E.
    Porta, Camillo
    Eto, Masatoshi
    Sternberg, Cora N.
    Rha, Sun Young
    He, Cixin S.
    Dutcus, Corina E.
    Smith, Alan
    Dutta, Lea
    Mody, Kalgi
    Motzer, Robert J.
    [J]. FUTURE ONCOLOGY, 2019, 15 (09) : 929 - 941
  • [3] Lenvatinib Combined With Pembrolizumab or Everolimus Lengthens Survival in Advanced Renal Cell Carcinoma
    Motzer, Robert J.
    Choueiri, Toni
    [J]. ONCOLOGY-NEW YORK, 2021, 35 (04): : 220 - 222
  • [4] Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma
    Hindie, Elif
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (03): : 287 - 287
  • [5] Cost-Effectiveness of Lenvatinib Plus Pembrolizumab or Everolimus as First-Line Treatment of Advanced Renal Cell Carcinoma
    Wang, Ye
    Wang, Hao
    Yi, Manman
    Han, Zhou
    Li, Li
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] New drug approval: Lenvatinib plus pembrolizumab for advanced renal cell carcinoma
    Saillant, Arnaud
    Borchiellini, Delphine
    [J]. BULLETIN DU CANCER, 2022, 109 (7-8) : 737 - +
  • [7] PHASE 3 STUDY OF PEMBROLIZUMAB plus BELZUTIFAN plus LENVATINIB OR PEMBROLIZUMAB/QUAVONLIMAB plus LENVATINIB VERSUS PEMBROLIZUMAB plus LENVATINIB AS FIRST-LINE TREATMENT FOR ADVANCED RENAL CELL CARCINOMA
    Choueiri, Toni
    Plimack, Elizabeth
    Powles, Thomas
    Voss, Martin
    Gurney, Howard
    Silverman, Rachel
    Perini, Rodolfo
    Rodriguez-Lopez, Karla
    Rini, Brian
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A447 - A447
  • [8] The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma
    Jacob, Allen
    Shook, Jaret
    Hutson, Thomas
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (04) : 365 - 372
  • [9] Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma
    Ged, Yasser
    Lee, Chung-Han
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (10) : 1049 - 1059
  • [10] Phase 3 study of first-line treatment with pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib for advanced renal cell carcinoma (RCC).
    Choueiri, Toni K.
    Plimack, Elizabeth R.
    Powles, Thomas
    Voss, Martin H.
    Gurney, Howard
    Silverman, Rachel Kloss
    Perini, Rodolfo F.
    Rodriguez-Lopez, Karla
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345